Loading
MEF2B (Myocyte-specific enhancer factor 2B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Mantle cell lymphoma.
Transcriptional activator which binds specifically to the MEF2 element, 5'-YTA[AT](4)TAR-3', found in numerous muscle-specific genes. Activates transcription via this element. May be involved in muscle-specific and/or growth factor-related transcription.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant. IntOGen calls it a driver in 5 cohorts (2 activating, 3 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.
In plain words · MEF2B (Myocyte-specific enhancer factor 2B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Mantle cell lymphoma.
MEF2B (Myocyte-specific enhancer factor 2B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Mantle cell lymphoma.
Transcriptional activator which binds specifically to the MEF2 element, 5'-YTA[AT](4)TAR-3', found in numerous muscle-specific genes. Activates transcription via this element.
No product in this corpus aims at MEF2B yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA MEF2B: RNA tissue enriched (lymphoid tissue 37 nTPM); high antibody staining in 2 normal tissues; highest cancer staining lymphoma (3 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q02080; CIViC gene MEF2B; IntOGen MEF2B; Human Protein Atlas MEF2B tissue; Open Targets ENSG00000213999 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Pollock et al, Genes Dev, 1991, "Human SRF-related proteins: DNA-binding properties and potential regulatory targets". Source.
Sources: HGNC HGNC:6995 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q02080 (protein name, function text, keywords and locations (REST API)); CIViC gene MEF2B (2 evidence items, 0 assertions, 1 variants; diseases: Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000213999 (per-cancer scores at or above 0.5: non-Hodgkin lymphoma 0.56 (GraphQL API, CC0)); IntOGen MEF2B (driver in 5 cohorts (Act 2, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcriptional activator which binds specifically to the MEF2 element, 5'-YTA[AT](4)TAR-3', found in numerous muscle-specific genes. Activates transcription via this element. May be involved in muscle-specific and/or growth factor-related transcription. Location: Nucleus (UniProt). Locus 19p13.11 (HGNC).
RNA: tissue enriched (lymphoid tissue 37 nTPM), detected in many normal tissues.
Medium only: lung cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"MEF2B" OR ABSTRACT:"MEF2B" OR TITLE:"myocyte enhancer factor 2B" OR ABSTRACT:"myocyte enhancer factor 2B" OR TITLE:"Myocyte-specific enhancer factor 2B" OR ABSTRACT:"Myocyte-specific enhancer factor 2B" OR TITLE:"RSRFR2" OR ABSTRACT:"RSRFR2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MEF2B, not a curated reading list.